Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

EPT Disclosure

16 Sep 2008 08:32

RNS Number : 5096D
Liberum Capital Limited
16 September 2008
 

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS 

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

1. KEY INFORMATION

Name of exempt principal trader

Liberum Capital Limited

Company dealt in

Flying Brands

Class of relevant security to which the dealings being disclosed relate (Note 1)

Units comprising 1 ordinary 1p share and 1 A ordinary of 0.005p share

Date of dealing

15/09/08

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

9,811 0.04%

0 0%

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

9,811 0.04%

0 0%

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

Class of relevant security:

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Rights to subscribe (Note 2)

Class of relevant security:

Details

3. DEALINGS (Note 3)

(a) Purchases and sales

Purchase/sale

Number of securities

Price per unit (Note 4)

Purchase

1200

0.63p

(b) Derivatives transactions (other than options)

Product name, 

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price 

Type, e.g. American, European etc.

Expiry 

date

Option money

paid/received per unit (Note 4) 

(ii) Exercising

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 4)

(d) Other dealings (including new securities) (Note 3)

Nature of transaction (Note 7)

Details

Price per unit (if applicable) (Note 4)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

Date of disclosure

16/09/08

Contact name

Carl Chambers 

Telephone number

020 3100 2000

Name of offeree/offeror with which connected

West Coast Capital

Nature of connection (Note 9)

Adviser

Notes

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMSFSSWMSASEDU
Date   Source Headline
2nd Sep 20217:00 amRNSBoard Changes
1st Sep 202110:00 amRNSStart of Trading on the OTCQB Venture Market
27th Aug 20219:57 amRNSHalf Yearly Report
11th Jun 20214:41 pmRNSSecond Price Monitoring Extn
11th Jun 20214:36 pmRNSPrice Monitoring Extension
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:05 amRNSSecond Price Monitoring Extn
11th Jun 202111:00 amRNSPrice Monitoring Extension
11th Jun 20218:00 amRNSIQAI Awarded “Gad-Free” Patent
4th Jun 20217:00 amRNSIB Software Chosen by LA County Hospital
19th May 202112:06 pmRNSResult of AGM
27th Apr 20213:27 pmRNSNotice of AGM
20th Apr 202110:21 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:27 amRNSIQAI commits to Phase 1 study
6th Apr 20217:00 amRNSFive Year NCI Award Grant to IB
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20212:05 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 20219:05 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
28th Jan 20217:00 amRNS"Gad Free" Imaging Update
25th Jan 202111:01 amRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSTechnology Portfolio Update
7th Jan 20212:06 pmRNSSecond Price Monitoring Extn
7th Jan 20212:00 pmRNSPrice Monitoring Extension
31st Dec 202012:41 pmRNSSecond Price Monitoring Extn
31st Dec 202012:36 pmRNSPrice Monitoring Extension
31st Dec 202011:00 amRNSPrice Monitoring Extension
10th Dec 202010:41 amRNSDirector Dealing and CLN Conversion - Correction
9th Dec 20202:05 pmRNSSecond Price Monitoring Extn
9th Dec 20202:01 pmRNSPrice Monitoring Extension
9th Dec 20209:02 amRNSDirector Dealing and Conversion of Loan Notes
7th Dec 202011:25 amRNSDirector Dealing
4th Dec 20204:52 pmRNSIssue of shares to Mayo Clinic
3rd Dec 20207:01 amRNSRelease of StoneChecker 20.12
26th Nov 20207:00 amRNSIMAGING BIOMETRICS UPGRADES IB CLINIC™ SOFTWARE
23rd Nov 20204:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20204:36 pmRNSPrice Monitoring Extension
23rd Nov 20202:06 pmRNSSecond Price Monitoring Extn
23rd Nov 20202:00 pmRNSPrice Monitoring Extension
23rd Nov 20201:45 pmRNSLSN Software is now CE Mark Approved
23rd Nov 202011:06 amRNSSecond Price Monitoring Extn
23rd Nov 202011:00 amRNSPrice Monitoring Extension
20th Nov 202011:05 amRNSSecond Price Monitoring Extn
20th Nov 202011:00 amRNSPrice Monitoring Extension
20th Nov 20209:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.